Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
Your view on ADAPY
Overview
What the company does, where it operates, and who runs it.
About Adaptimmune Therapeutics plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher James Hill
- Headquarters
- 60 Jubilee Avenue, Abingdon, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher James Hill
- Headquarters
- 60 Jubilee Avenue, Abingdon, GB
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer.
The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Adaptimmune Therapeutics plc, and the rating behind it. ADAPY last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Adaptimmune Therapeutics plc. Starting points for Adaptimmune Therapeutics plc: EPS -$0.30, beta 2.47 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Adaptimmune Therapeutics plc. Adaptimmune Therapeutics plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Adaptimmune Therapeutics plc. Trailing twelve-month EPS for Adaptimmune Therapeutics plc stands at -$0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Adaptimmune Therapeutics plc. Adaptimmune Therapeutics plc has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Adaptimmune Therapeutics plc valued side by side against its closest peers. Adaptimmune Therapeutics plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Adaptimmune Therapeutics plc, and how their positions are changing. At a $3.6M market value, institutional positions materially move Adaptimmune Therapeutics plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Adaptimmune Therapeutics plc executives and directors. Shares of Adaptimmune Therapeutics plc have traded between $0.0010 and $0.62 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Adaptimmune Therapeutics plc. Adaptimmune Therapeutics plc is a $3.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Adaptimmune Therapeutics plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Adaptimmune Therapeutics plc. Coverage tracks Adaptimmune Therapeutics plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.